Stabilized pharmaceutical composition containing bupropion
Patent 5731000 Issued on March 24, 1998. Estimated Expiration Date: 
March 22, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 22, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References Re33994 3819706 3885046 Compounds and methods of making same Compounds and methods of making them Compounds and methods of making Prolactin suppression in mammals 3H Labeled compounds Radioactive nuclide labeled propiophenone compounds Bupropion radioimmunoassay, and kit InventorsAssigneeApplicationNo. 586916 filed on 03/22/1996US Classes:424/451, Capsules (e.g., of gelatin, of chocolate, etc.)424/434, Mucosal (e.g., nasal, etc.)424/453, Telescoping two piece424/456, Gelatin424/457, Sustained or differential release424/465, With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)424/476, Containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof (e.g., chocolate)424/489Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)ExaminersPrimary: Page, Thurman K.Assistant: Benston, William E. Jr. Attorney, Agent or FirmForeign Patent References
International ClassA61K 009/48Foreign Application Priority Data1993-07-30 GBAbstractThis application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.Other References
| |
